key: cord-0015021-7i048up8
authors: King, Carina; Einhorn, Lena; Brusselaers, Nele; Carlsson, Marcus; Einhorn, Stefan; Elgh, Fredrik; Frisén, Jonas; Gustafsson, Åke; Hanson, Stefan; Hanson, Claudia; Hedner, Thomas; Isaksson, Olle; Jansson, Anders; Lundkvist, Åke; Lötvall, Jan; Lundback, Bo; Olsen, Björn; Söderberg-Nauclér, Cecilia; Wahlin, Anders; Steineck, Gunner; Vahlne, Anders
title: COVID-19—a very visible pandemic
date: 2020-08-06
journal: Lancet
DOI: 10.1016/s0140-6736(20)31672-x
sha: 3e8759d488cd32dd3569fdedff2a0deb40a6a525
doc_id: 15021
cord_uid: 7i048up8

nan

Submissions should be made via our electronic submission system at http://ees.elsevier.com/ thelancet/ www.thelancet.com Vol 396 August 8, 2020 e15

We read the Correspondence by Johan Giesecke, 1 a senior consultant to the Swedish Public Health Agency, with considerable concern. First, Giesecke correctly placed the Swedish death toll at less than the UK, Spain, and Belgium, and at more than its Nordic neighbours. But he did not acknowledge the scale of these differences. Despite similar epidemic start dates, population densities, and cultures, at the time of writing, Sweden had reported 7 times more COVID-19 deaths per person than Finland and Norway, and 3 times more than Denmark.

Secondly, to state that 98-99% of people infected with COVID-19 are "unaware or uncertain of having had the infection" 1 dangerously conflates asymptomatic cases with unconfirmed cases, and dismisses the lived experience of milder infections. Although a summary of 13 studies estimates that 56% of cases are asymptomatic at the point of testing, many go on to develop symptoms. 2 For Giesecke 1 to state that "COVID-19 is spreading like wildfire in all countries, but we do not see it" is contradictory.

Giesecke's further assertion that, as of April 29, 2020, 20-25% of the Stockholm region have been infected only serves to reinforce his opinion of unreported cases. But this assertion is based on a narrow view of available data at that time. Of the three preliminary and unpublished serology studies from Stockholm in April, 2020, only one study, testing 527 of 2000 healthcare workers at a single hospital, is close to this estimate (20% seropositive). 3 However, community estimates range from 7·5% to 10%, and suggest considerable clustering. 4, 5 Indeed, serology data from other European settings in March and April, 2020, report low antibody prevalence, from less than 1·0% to 2·7% among tested blood donors; 6,7 5·5% from a random population sample in Geneva; 8 and 11·2% from health-care workers in Spain. 9 The hotspot of Gangelt in Germany reported 15% patients with an infection, 10 substantially lower than the assumed 50-70% threshold needed for herd immunity. Therefore, it seems implausible to suggest that Europe is past the peak because of so-called silently acquired herd immunity, rather than as a result of active intervention.

Finally, the conclusion that stopping the spread of COVID-19 is futile ignores clear examples from New Zealand, Taiwan, Iceland, and Vietnam. It is disingenuous to dismiss these considerable successes of COVID-19 containment and, at least temporarily, suppression. The threat of future outbreaks is of course a real concernlook to Singapore for a stark warning.

But to state that slowing down the progression of COVID-19 is futile is cynical, as it implies that painfully acquired knowledge and efforts to develop or repurpose drugs and treatments will amount to nothing. JF reports personal fees from 10X Genomics, unrelated to this Correspondence. JL reports equity from Codiak BioSciences and Exocure Biosciences, and personal fees from Vesicle Biosciences, unrelated to this Correspondence; and developing a vaccine candidate against severe acute respiratory syndrome coronavirus 2. All other authors declare no competing interests.

The invisible pandemic

Getting a handle on asymptomatic SARS-CoV-2 infection

Var femte anställd på Danderyds sjukhus har haft smittan

10 procent av stockholmarna smittade

Färre än väntat har antikroppar mot corona

Herd immunity is not a realistic exit strategy during a COVID-19 outbreak

Neutralising antibodies to SARS coronavirus 2 in Scottish blood donors -a pilot study of the value of serology to determine population exposure

Seroprevalence COVID-19: premiere estimation de la prevalence d'anticorsp anti SARS-CoV-2 IgG dans la population Genevoise

Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital

Infection fatality rate of SARS-CoV-2 infection in a German community with a superspreading event